Imlygic market forecast points to growth in melanoma treatment demand

The Business Research Company says the Imlygic market is set for growth through 2035 as melanoma diagnoses rise, cancer research funding increases and oncolytic viral therapies gain traction. North America led the market in 2025, while the report highlights combination trials, localized tumor targeting and injectable cancer treatments as key trends.

Why it matters: - Imlygic is used for unresectable melanoma, so demand is tied to the growing burden of advanced skin cancer. - The market’s trajectory reflects broader momentum in immunotherapy and viral oncology, two areas that could expand treatment options for hard-to-treat cancers. - The report points to rising melanoma cases, higher research spending and stronger healthcare infrastructure as factors that can support adoption.

What happened: - The Business Research Company released its Imlygic Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the Imlygic market grew in prior years because of limited options for unresectable melanoma, early immunotherapy breakthroughs, rising melanoma cases, validation of viral oncology and broader use in cancer treatment centers. - The report forecasts further growth from 2026 to 2030, with the market shaped by cancer immunotherapy pipelines, combination oncology trials, investment in viral therapies, more melanoma diagnoses and advances in genetic engineering. - North America was the largest regional market for Imlygic in 2025. - The analysis also covers Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa.

The details: - Imlygic is a prescription drug for certain cancers. - Imlygic is an oncolytic viral therapy that uses a genetically altered virus to infect and destroy cancer cells. - Imlygic is derived from herpes simplex virus type 1, or HSV-1. - The drug is approved for melanoma tumors that cannot be removed surgically. - Imlygic, also known as talimogene laherparepvec, is injected directly into melanoma tumors to destroy them locally and stimulate an immune response elsewhere in the body. - The report cites December 2023 data from the US National Library of Medicine showing melanoma cases in the EU-27 reached 101,510 in 2022 and are projected to rise to 115,540 by 2040. - The report says global healthcare infrastructure growth supports the market because Imlygic needs specialized storage, administration and coordinated delivery. - Cross River Therapy said in September 2024 that the U.S. pharmaceutical industry generated $550 billion in revenue, while medicine spending by Americans is projected to rise from $576.9 billion in 2021 to between $605 billion and $635 billion by 2025. - The report says cancer research and development funding is rising because of the global cancer burden, demand for new treatments and progress in precision medicine. - The US National Cancer Institute reported in July 2025 that available funding for fiscal year 2023 rose 5.7% to $7.2 billion, including $216 million from the Cures Act. - The report highlights oncolytic viral therapies, immuno-oncology approaches, injectable cancer treatments, localized tumor targeting and combination therapy strategies as major forecast-period trends. - The report says its 2026 editions now include market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, key technology analysis and future trend analysis. - The report offers a free sample and full report through the company’s sample request page and the full report page.

Between the lines: - The report frames Imlygic as part of a wider shift toward therapies that attack tumors locally while also activating immune responses. - The focus on combination trials suggests Imlygic may be increasingly evaluated as part of broader treatment regimens rather than as a stand-alone option. - The added strategic tools in the 2026 report signal that the market is being positioned for investors and business planners, not just clinicians.

What's next: - The report expects growth to continue as melanoma incidence rises and more cancer immunotherapy products move through development. - More investment in viral therapies and genetic engineering could expand the clinical role of oncolytic treatments like Imlygic. - The company says the market analysis will continue to track regional opportunities and technology shifts across the forecast period.